Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs.

References

1. Jester BJ, Uyeki TM, Jernigan DB. Fifty years of influenza A(H3N2) following the pandemic of 1968. Am J Public Health 2020; 110:669–676 [View Article] [PubMed]
   [Google Scholar]
2. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 influenza season. Cell Rep 2015; 12:1–6 [View Article] [PubMed]
   [Google Scholar]
3. Yang J, Huang Y, Liu S. Investigational antiviral therapies for the treatment of influenza. Expert Opin Investig Drugs 2019; 28:481–488 [View Article] [PubMed]
   [Google Scholar]
4. Beard KR, Brendish NJ, Clark TW. Treatment of influenza with neuraminidase inhibitors. Curr Opin Infect Dis 2018; 31:514–519 [View Article] [PubMed]
   [Google Scholar]
5. Stevaert A, Naesens L. The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design. Med Res Rev 2016; 36:1127–1173 [View Article] [PubMed]
   [Google Scholar]
6. Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis 2019; 32:176–186 [View Article] [PubMed]
   [Google Scholar]
7. Lee LYY, Zhou J, Frise R, Goldhill DH, Koszalka P et al. Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission. PLoS Pathog 2020; 16:e1008395
   [Google Scholar]
8. Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res 2018; 160:109–117 [View Article] [PubMed]
   [Google Scholar]
9. Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 2018; 379:913–923 [View Article] [PubMed]
   [Google Scholar]
10. Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2020; 20:1204–1214 [View Article] [PubMed]
    [Google Scholar]
11. Hirotsu N, Sakaguchi H, Sato C, Ishibashi T, Baba K. Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes. Clin Infect Dis 2020; 71:971–981 [View Article] [PubMed]
    [Google Scholar]
12. Chesnokov A, Patel MC, Mishin VP, De La Cruz JA, Lollis L. Replicative fitness of seasonal influenza A viruses with decreased susceptibility to baloxavir. J Infect Dis 2020; 221:367–371 [View Article] [PubMed]
    [Google Scholar]
13. Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC. Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 2020; 221:346–355 [View Article] [PubMed]
    [Google Scholar]
14. Gubareva LV, Mishin VP, Patel MC, Chesnokov A, Nguyen HT. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill 2019; 24: [View Article] [PubMed]
    [Google Scholar]
15. Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep 2018; 8:9633 [View Article] [PubMed]
    [Google Scholar]
16. Takashita E, Kawakami C, Ogawa R, Morita H, Fujisaki S. Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019. Euro Surveill 2019; 24: [View Article] [PubMed]
    [Google Scholar]
17. Takashita E, Ichikawa M, Morita H, Ogawa R, Fujisaki S. Human-to-Human transmission of influenza A(H3N2) virus with reduced susceptibility to baloxavir, Japan, February 2019. Emerg Infect Dis 2019; 25:2108–2111 [View Article] [PubMed]
    [Google Scholar]
18. Checkmahomed L, Carbonneau J, Venable MC, Baz M. Impact of the baloxavir-resistant polymerase acid I38T substitution on the fitness of contemporary influenza A(H1N1)pdm09 and A(H3N2) strains. J Infect Dis 2020; 221:63–70 [View Article] [PubMed]
    [Google Scholar]
19. Imai M, Yamashita M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kiso M. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets. Nat Microbiol 2020; 5:27–33 [View Article] [PubMed]
    [Google Scholar]
20. Jones JC, Pascua PNQ, Fabrizio TP, Marathe BM, Seiler P. Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility. Proc Natl Acad Sci U S A 2020; 117:8593–8601 [View Article] [PubMed]
    [Google Scholar]
21. Bouvier NM, Lowen AC. Animal models for influenza virus pathogenesis and transmission. Viruses 2010; 2:1530–1563 [View Article] [PubMed]
    [Google Scholar]
22. Baz M, Carbonneau J, Lavigne S, Couture C. Synergistic PA and HA mutations confer mouse adaptation of a contemporary A/H3N2 influenza virus. Sci Rep 2019; 9:16616 [View Article] [PubMed]
    [Google Scholar]
23. Hatakeyama S, Sakai-Tagawa Y, Kiso M, Goto H, Kawakami C et al. Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol 2005; 43:4139–4146
    [Google Scholar]
24. Ann J, Abed Y, Beaulieu E, Bouhy X, Joly MH. Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets. Influenza Other Respir Viruses 2016; 10:122–126 [View Article] [PubMed]
    [Google Scholar]
25. Palmer DF DW, Coleman MT, Schild GC. Advanced Laboratory Techniques for Influenza Diagnosis Atlanta: Centers for Disease Control, US Department of Health, Education and Welfare; 1975
    [Google Scholar]
26. Taylor SC, Carbonneau J, Shelton DN, Boivin G. Optimization of Droplet Digital PCR from RNA and DNA extracts with direct comparison to RT-qPCR: Clinical implications for quantification of Oseltamivir-resistant subpopulations. Journal of virological methods, Comparative Study Evaluation Study 2015; 224:58–66
    [Google Scholar]
27. Lee LY, Zhou J, Koszalka P, Frise R, Farrukee R. Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model. PLoS Pathog 2021; 17:e1009527 [View Article] [PubMed]
    [Google Scholar]
28. Takada K, Kawakami C, Fan S, Chiba S, Zhong G. A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses. Nat Microbiol 2019; 4:1268–1273 [View Article] [PubMed]
    [Google Scholar]
29. Lowen AC, Mubareka S, Tumpey TM, Garcia-Sastre A, Palese P. The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A 2006; 103:9988–9992 [View Article] [PubMed]
    [Google Scholar]